Actinic cheilitis: Do stem cells have a role in its management? A case series.
Chieng CY., Mannapperuma N., Sayan A., Ilankovan V.
Retrospective Study, published in Br J Oral Maxillofac Surg (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Br J Oral Maxillofac Surg (2025)
- Country
- Scotland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40118757
- DOI
- 10.1016/j.bjoms.2025.02.004
Abstract (original English)
Actinic cheilitis (AC) is a premalignant mucosal lip condition that mainly affects the lower lip and has a high propensity of malignant transformation into squamous cell carcinoma. There is no gold standard for its management, but early intervention aims to minimise the risk of malignant transformation. Here we report our experience of utilising nanofat grafting in the management of AC. Retrospective data analysis was carried out between 2020 and 2024. Patients diagnosed with AC were treated with nanofat grafting. The nanofat preparation was harvested from the abdomen and prepared using the PureGraft® filtration system (Bimini Health Tech), and was infiltrated into the lips in two layers. Outcomes were assessed clinically. Seven patients were included in our analysis with a mean follow up of 23 months. All patients had had previous treatment for AC such as topical 5-fluororacil, steroids, laser ablation, and cryotherapy. Five of the seven received simultaneous nanofat grafting followed by erbium laser resurfacing at the same appointment. The others had nanofat grafting after laser resurfacing. Following the procedure all the patients had no further cracks, ulcerations, or erosions of the lips, with a good definition of the vermilion border, and all patients remained symptom free. The combination of nanofat grafting and laser resurfacing provides an alternative minimally invasiv
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.